309 Frequency and acceptance of CDSS-generated STOPP/START signals - SI Table SI1.1. Continued. STOPP criteria (n=79) All countries Belgium (BE) Switzerland (CH) Ireland (IE) The Netherlands (NL) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) D 11. Acetylcholinesterase inhibitors with a known history of persistent bradycardia (< 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil 6 50.0% 0 N/A 5 40.0% 1 100% 0 0% F 4. Oral elemental iron doses greater than 200 mg daily (e.g. ferrous fumarate> 600 mg/day, ferrous sulphate > 600 mg/day, ferrous gluconate> 1800 mg/day) 6 16.7% 0 N/A 0 N/A 1 0.0% 5 20.0% J 5. Oral oestrogens without progestogen in patients with intact uterus 6 16.7% 2 0% 4 25.0% 0 N/A 0 N/A C 11. NSAID with concurrent antiplatelet agent(s) without PPI prophylaxis 5 80.0% 0 N/A 5 80.0% 0 N/A 0 N/A D 2. Initiation of Tricyclic Antidepressants (TCAs) as first-line antidepressant treatment 5 40.0% 1 0% 2 100% 0 N/A 2 0% D 4. Selective serotonin re-uptake inhibitors (SSRI’s) with current or recent significant hyponatraemia i.e. serum Na+ < 130 mmol/l 5 20.0% 1 0% 4 25.0% 0 N/A 0 N/A L 3. Long-acting opioids without short-acting opioids for break-through pain 5 0% 1 0% 2 0% 2 0% 0 N/A B 1. Digoxin for heart failure with normal systolic ventricular function 4 25.0% 2 0% 2 50.0% 0 N/A 0 N/A 4
RkJQdWJsaXNoZXIy MTk4NDMw